Samaras P, et al. - This Phase I study aims to assess the safety, maximum tolerated dose, anti-tumour activity and immune status of a gemcitabine–chloroquine combination as a first- or late-line treatment in patients with metastatic or unresectable pancreatic cancer. Chloroquine addition to gemcitabine was well tolerated in this trial. The combination indicated promising effects on the clinical response to the anti-cancer chemotherapy. Researchers recommended further assessment of the efficacy of the gemcitabine–chloroquine combination.